Join CVMA Chapter 2 for a virtual evening of lymphoma CE with Douglas H. Thamm, VMD, DACVIM (oncology) from Colorado State University.

Lymphoma is a commonly encountered disease in animals. While conventional chemotherapy has the potential to induce remission and improve quality of life, relapse is common and novel treatments are needed to continue to improve outcome. This review will discuss recent modifications to conventional standard of care therapy for canine and feline lymphoma that can be immediately implemented, as well as cutting-edge immunotherapy and small molecule-based approaches that are in varying stages of regulatory approval.

Tuesday, April 20 | 7:00-8:00 p.m. (log in at 6:45 p.m.)
Virtual CE event (you will receive an email link from CVMA before the session)
1 CE credit

**This CE event will not be recorded and will only be available live on April 20.**

This event is FREE for all Chapter 2 members as a part of your CVMA Chapter 2 membership! 

Not a CVMA member but want access to free CE? Join now! colovma.org/membership

Learn more and register here: https://colovma.site-ym.com/events/EventDetails.aspx?id=1503196 

Presenter

Douglas H. Thamm, VMD, DACVIM (oncology)

Dr. Thamm is the Barbara Cox Anthony Professor of Oncology and Director of Clinical Research at the Colorado State University Flint Animal Cancer Center. He is also a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. He has authored over 150 peer-reviewed publications and 20 book chapters in veterinary and basic cancer research, is Co-Editor for the most recent edition of the textbook Withrow and MacEwen’s Small Animal Clinical Oncology, and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology.  His clinical and research interests include novel targeted therapies for animal and human cancer and ways to integrate these therapies with existing treatment.

Thank you, sponsor!